BioAmber Inc., a leader in renewable materials recently announced operational and financial results for the three months ended March 31, 2017.
Sales of bio-succinic acid were $2.1 million, a 46% increase over the same period last year.
There were 7 new clients that began buying bio-succinic acid in the quarter.
The plant attained a new throughput record, briefly surpassing 70% and saw a further reduction in variable costs relative to the previous quarter.
Research and Development expenses were $1.6 million for the quarter, a 16% decrease relative to the same period last year.
On January 27, 2017, the Company raised $20.1 million in gross proceeds from an equity offering, and used the proceeds to reimburse in full all outstanding corporate debt.
On April 28, 2017, $8.9 million was released from escrow as a result of the automatic exercise of a Special Warrant issued on December 30th, 2016.
On May 3, 2017, the Company’s shares became eligible for trading on the Toronto Stock Exchange under the symbol BIOA.
On May 9, 2017, the 8 million warrants that the Company had issued at the time of its initial public offering expired. None of the warrants were exercised prior to their expiry.
“Our first quarter of 2017 witnessed record throughput rates at the plant, combined with incremental decreases in our overall operating costs per unit sold,” stated Fabrice Orecchioni, BioAmber’s President, Chief Operations Officer and Interim-CEO. “In addition, our recent TSX Listing will provide greater liquidity and depth of distribution for our shareholders and potential new investors”, he added.
Q1 2017 Financial Results
Revenues for the quarter ended March 31, 2017 were $2.1 million. The 46% increase relative to the same period last year was driven by an increase in the quantity of bio-succinic acid sold from our Sarnia operations.
Cost of goods sold increased from $3.1 million for the quarter ended March 31, 2016 to $4.1 million for the quarter ended March 31, 2017, primarily due to an increase in the volume sold partially offset by a reduction in our production costs.
General and administrative expenses increased from $2.6 million for the quarter ended March 31, 2016 to $4.9 million for the quarter ended March 31, 2017. This was driven by one-time severance costs in connection with the departure of the CEO and CFO for a total of approximately $1.2 million, and additional non-cash stock-based compensation expense of $1.2 million resulting from accelerated vesting of stock-options associated with the departures.
Research and development expenses were $1.6 million for the quarter ended March 31, 2017, down from $1.8 million for the same period last year. This decrease is primarily explained by a reduction in research and development expenses to support the commissioning and start-up of the Sarnia facility.
Sales and marketing expenses were $642,000 for the quarter ended March 31, 2017, down from $1.2 million for the same period last year. This was due to the expanded commercial role that Mitsui has assumed, particularly in Asia, which allowed the Company to reduce the size of its global commercial team, resulting in a decrease in sales and marketing salaries, benefits and associated costs, including stock-based compensation and travel expenses.
The Company registered financial income of $8.9 million for the three months ended March 31, 2017 as compared to a financial charge of $3.4 million for the same period last year. This variation of $12.3 million was mainly due to the non-cash mark-to-market adjustment change of $12.7 million for the IPO warrants, the June 2009 Warrants, the April 2011 Warrants and the 2017 Warrants. This income was partially offset by issuance costs of $350,000 associated with the 2017 Warrants.
The Company also incurred a $745,000 non-cash gain on debt extinguishment from the renegotiation of our FEDDEV loan, offset by a loss on the Bridging demand loan repayment.
The Company recorded a net income attributable to BioAmber Inc. shareholders of $106,000, or an income of $0.003 per share for the quarter ended March 31, 2017, compared to a net loss of $10.9 million, or a loss of $0.39 per share for the same period last year.
The Adjusted Net Loss Attributable to BioAmber Inc. Shareholders for the quarter ended March 31, 2017 was $10.5 million, or a loss of $0.31 per share, compared to an Adjusted Net Loss Attributable to BioAmber Inc. Shareholders of $8.1 million, or a loss of $0.29 per share for the three months ended March 31, 2016. Adjusted Net Loss Attributable to BioAmber Inc. Shareholders is a non-GAAP financial metric that excludes (i) the impact of the change in fair value of the IPO, Legacy and 2017 Warrants and (ii) the non-cash gain on debt extinguishment.
Please refer to Annex A: “Non-GAAP Financial Information—Adjusted Net Loss Attributable to BioAmber Inc. Shareholders” for more information regarding this non-GAAP financial metric.
Webcast and Conference Call Information
BioAmber will discuss these results on a live audio webcast, which will be available on the Internet to investors, members of the news media and the general public at 4:30 p.m. Eastern Time on May 9, 2017. To access the webcast of the conference call, go to the company’s website, www.bio-amber.com. Audio of the teleconference is also available by dialing:
North American callers: +1 (888) 390-0546 International callers: +1 (416) 764-8688
Teleconference replays will be available through May 16, 2017: Domestic: +1-888-390-0541
International: +1 416-764-8677 Passcode: 007413 #. A replay of the webcast will also be available approximately two hours after the conclusion of the live webcast on BioAmber’s website, for a period of 30 days.